Lilly agrees to $690M drug settlement

Eli Lilly has agreed to pay $690 million to resolve some 8,000 claims that its antipsychotic Zyprexa triggered diabetes-related health problems. The drug company did not admit any wrongdoing in the settlement, which comes just months before the first of scores of lawsuits were scheduled for trial. The settlement would resolve about 75 percent of the cases faced by Lilly. Most of the claims revolve around accusations that prior to September 2003 the company didn't adequately warn patients about possible side effects of the drug, which was used to treat schizophrenia.

- read this story from the Indianapolis Star

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.